| Date | Time | Source | Headline | Symbol | Company |
| 09/10/2024 | 7:56AM | PR Newswire (US) | Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress | NASDAQ:PAVM | PAVmed Inc |
| 09/03/2024 | 7:51AM | PR Newswire (US) | Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health | NASDAQ:PAVM | PAVmed Inc |
| 08/20/2024 | 8:16AM | PR Newswire (US) | Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer | NASDAQ:PAVM | PAVmed Inc |
| 08/13/2024 | 8:18AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PAVM | PAVmed Inc |
| 08/13/2024 | 8:16AM | PR Newswire (US) | The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer | NASDAQ:PAVM | PAVmed Inc |
| 08/13/2024 | 8:01AM | PR Newswire (US) | PAVmed Provides Business Update and Second Quarter 2024 Financial Results | NASDAQ:PAVM | PAVmed Inc |
| 08/12/2024 | 4:08PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:PAVM | PAVmed Inc |
| 08/12/2024 | 8:07AM | PR Newswire (US) | Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results | NASDAQ:PAVM | PAVmed Inc |
| 08/08/2024 | 8:31AM | PR Newswire (US) | Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event | NASDAQ:PAVM | PAVmed Inc |
| 08/06/2024 | 8:15AM | PR Newswire (US) | Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing | NASDAQ:PAVM | PAVmed Inc |
| 08/05/2024 | 8:15AM | PR Newswire (US) | Lucid Diagnostics to Participate in Upcoming Investor Conferences | NASDAQ:PAVM | PAVmed Inc |
| 07/30/2024 | 8:15AM | PR Newswire (US) | PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 | NASDAQ:PAVM | PAVmed Inc |
| 07/29/2024 | 8:15AM | PR Newswire (US) | Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024 | NASDAQ:PAVM | PAVmed Inc |
| 07/23/2024 | 8:01AM | PR Newswire (US) | Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume | NASDAQ:PAVM | PAVmed Inc |
| 07/11/2024 | 8:31AM | PR Newswire (US) | Lucid Diagnostics Launches New Corporate Website | NASDAQ:PAVM | PAVmed Inc |
| 07/02/2024 | 7:55AM | PR Newswire (US) | Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population | NASDAQ:PAVM | PAVmed Inc |
| 06/13/2024 | 7:58AM | PR Newswire (US) | PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | NASDAQ:PAVM | PAVmed Inc |
| 06/12/2024 | 8:05AM | PR Newswire (US) | 4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing | NASDAQ:PAVM | PAVmed Inc |
| 05/13/2024 | 8:43PM | PR Newswire (US) | PAVmed Provides Business Update and First Quarter 2024 Financial Results | NASDAQ:PAVM | PAVmed Inc |
| 05/13/2024 | 8:00AM | PR Newswire (US) | Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results | NASDAQ:PAVM | PAVmed Inc |
| 05/09/2024 | 7:49AM | PR Newswire (US) | Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall | NASDAQ:PAVM | PAVmed Inc |
| 05/07/2024 | 7:39AM | PR Newswire (US) | Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors | NASDAQ:PAVM | PAVmed Inc |
| 05/03/2024 | 8:35AM | PR Newswire (US) | PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 | NASDAQ:PAVM | PAVmed Inc |
| 05/02/2024 | 8:35AM | PR Newswire (US) | Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 | NASDAQ:PAVM | PAVmed Inc |
| 05/02/2024 | 7:49AM | PR Newswire (US) | Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing | NASDAQ:PAVM | PAVmed Inc |
| 04/30/2024 | 7:35AM | PR Newswire (US) | PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | NASDAQ:PAVM | PAVmed Inc |
| 04/29/2024 | 8:47AM | PR Newswire (US) | Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month | NASDAQ:PAVM | PAVmed Inc |
| 04/08/2024 | 8:30AM | PR Newswire (US) | Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:PAVM | PAVmed Inc |
| 03/26/2024 | 7:32PM | PR Newswire (US) | PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:PAVM | PAVmed Inc |
| 03/21/2024 | 9:30AM | PR Newswire (US) | Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population | NASDAQ:PAVM | PAVmed Inc |